RxDoctor Payments Data

Refaat El Said, MD

Neurology · Orlando, FLNPI 1720179393

Payments from drug & device makers

$812,173in general payments, 2019–2025

Across 266 payments — averaging $3053.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$798K
  • Immedica Pharma US, Inc.$6K
  • DIXI Medical USA Corp$2K
  • AbbVie$1K
  • Neuropace, Inc.$1K
  • Eisai Inc.$516
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$5206%
  • Food & beverage$7,77593%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$812,173 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$102,841
Medicare patients
157
Services billed
563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FirdapseAmifampridine Phosphate11$461,431
RebifInterferon Beta-1a/Albumin12$124,606
EpidiolexCannabidiol (Cbd)23$124,404
AptiomEslicarbazepine Acetate37$75,067
Nurtec OdtRimegepant Sulfate39$65,958
Lamictal XrLamotrigine12$64,938
Aimovig AutoinjectorErenumab-Aooe53$60,062
QuliptaAtogepant45$46,624
XcopriCenobamate37$43,562
UbrelvyUbrogepant29$41,017
Keppra XrLevetiracetam16$29,933
BriviactBrivaracetam17$26,561
FycompaPerampanel13$17,222
EliquisApixaban11$7,602
Memantine Hcl249$6,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Catalyst Pharmaceuticals, Inc.Firdapse$26$461,43111 claims
EMD Serono, Inc.Rebif$13$124,60612 claims
AbbVieQulipta, Ubrelvy$1,395$87,64174 claims
Sunovion Pharmaceuticals Inc.Aptiom$321$75,06737 claims
PfizerNurtec Odt, Eliquis$332$73,55950 claims
SK Life Science, Inc.Xcopri$127$43,56237 claims
UCB, Inc.Briviact$374$26,56117 claims
Eisai Inc.Fycompa$516$17,22213 claims
Amneal Pharmaceuticals LLCRytary$76$1,32211 claims
Upsher-smith Laboratories LLCTopiramate$97$77843 claims
Lilly USA, LLCOlanzapine$126$18915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →